Active Biotech to Present at BIO 2007 Annual International Convention
Lund, Sweden - 3 May 2007 - Active Biotech (Stockholm: ACTI.ST) management will present at the BIO 2007 Annual International Convention in Boston (USA) on Tuesday, 8 May at 11:00 am in Room D, Boston Convention & Exhibition Center.
Sven Andréasson, President and CEO will give an overview of Active Biotech's projects within the areas of autoimmune/inflammatory diseases and cancers. The presentation will provide an update on the company's clinical projects:
laquinimod (in partnership with Teva Pharmaceutical Industries Ltd) - an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis; and
ANYARA - for use in cancer targeted therapy, with the primary indication renal cancer.
In addition, the presentation will address other key projects that Active Biotech has in clinical development, including the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® (in partnership with MediGene AG) primarily for RA as well as the project I-3D in pre-clinical development (in partnership with Chelsea Therapeutics International Ltd).
Company management will be present at the BIO2007 Business Forum.
Attendees are invited to visit the Active Biotech booth #2065 in the Scandinavian Pavilion, to meet company representatives and learn more about Active Biotech.
Lund, Sweden, 3 May 2007
Active Biotech AB (publ)
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50